Literature DB >> 177710

Cytomegalovirus infection in patients receiving immunosuppressive therapy for rheumatologic disorders.

J N Dowling, A R Saslow, J A Armstrong, M Ho.   

Abstract

Evidence of cytomegalovirus infection was sought in 131 patients attending a rheumatology clinic, 211 blood donors, and 14 patients before and after the initiation of cytotoxic immunosuppressive therapy for a rheumatologic condition. The titer of complement-fixing antibody to cytomegalovirus was significantly related to age and sex, but not to rheumatologic disease. After adjustment for age and sex differences, the proportion of patients treated with corticosteroids who had measurable antibody was lower than that of controls (P less than 0.025). Immunosuppressive therapy with azathioprine or cyclophosphamide did not affect the proportion of patients with antibody, but there was a significantly increased titer of antibody in those who were seropositive (P = 0.04). Cytomegalovirus was isolated from the urine of 20% of patients receiving cytotoxic immunosuppressive drugs, but not from any of the patients receiving corticosteroids or neither form of therapy (P = 0.001). Eight of 14 patients followed prospectively after the initiation of therapy with immunosuppressive drugs became infected with cytomegalovirus as demonstrated by a fourfold or greater rise in complement-fixing titer, viruria, or both. Seven of the eight patients were seropositive before therapy, a finding suggesting that immunosuppression acts largely by reactivating latent infection. It is postulated that immunosuppressive agents alone may account for a large proportion of cytomegalovirus infections seen after allograft transplantation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 177710     DOI: 10.1093/infdis/133.4.399

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Comparison of the Histopaque-1119 method with the Plasmagel method for separation of blood leukocytes for cytomegalovirus isolation.

Authors:  M Slifkin; R Cumbie
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

2.  Cell-mediated immunity to cytomegalovirus in immunocompromised patients: effect of radiation or chemotherapy.

Authors:  Y Agatsuma; P Fitzpatrick; A Kaul; R Kaul; R Kohli; A V Paves; P L Ogra
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

Review 3.  Herpesviruses.

Authors:  M C Timbury; E Edmond
Journal:  J Clin Pathol       Date:  1979-09       Impact factor: 3.411

4.  Cytomegalovirus in immune compromised hosts.

Authors: 
Journal:  Br Med J       Date:  1977-04-23

5.  Comparison of rates of virus isolation from leukocyte populations separated from blood by conventional and Ficoll-Paque/Macrodex methods.

Authors:  C L Howell; M J Miller; W J Martin
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

6.  Virus infections after transplantation in man. Brief review.

Authors:  M Ho
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

7.  Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. I. Prolonged suppression of in vitro lymphocyte responses against CMV infected fibroblasts related to previous secondary CMV infection.

Authors:  H W Roenhorst; J M Middeldorp; J M Beelen; J Schirm; A M Tegzess; T H The
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

8.  Patient with rheumatoid arthritis on methotrexate with multiple infecting organisms causing gastritis.

Authors:  Robert Husney; Vladamir Privman; Douglas Sepkowitz
Journal:  BMJ Case Rep       Date:  2013-07-31

9.  Effects of immunosuppression with cyclophosphamide on acute murine cytomegalovirus infection and virus-augmented natural killer cell activity.

Authors:  M K Selgrade; M J Daniels; P C Hu; F J Miller; J A Graham
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

Review 10.  Cytomegalovirus infection in critically ill patients: a systematic review.

Authors:  Ryosuke Osawa; Nina Singh
Journal:  Crit Care       Date:  2009-05-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.